AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|AAPL348.22+4.23 (+1.23%) ▲|ABBV285.19+0.39 (+0.14%) ▲|ABT102.51+2.00 (+1.99%) ▲|ACN258.74+18.48 (+7.69%) ▲|ADBE270.55+15.49 (+6.07%) ▲|AMAT375.58-33.36 (-8.16%) ▼|AMD507.93-44.79 (-8.10%) ▼|AMGN447.28+8.94 (+2.04%) ▲|AMT181.57+3.93 (+2.21%) ▲|AMZN250.38-11.99 (-4.57%) ▼|AVGO323.24-14.56 (-4.31%) ▼|AXP325.17+1.56 (+0.48%) ▲|BA187.55-4.73 (-2.46%) ▼|BAC51.08+0.30 (+0.59%) ▲|BKNG161.10+2.72 (+1.72%) ▲|BLK1,137.29-12.31 (-1.07%) ▼|BMY63.00+1.88 (+3.08%) ▲|BNY145.32-0.53 (-0.36%) ▼|BRK-B546.97+7.98 (+1.48%) ▲|C122.51-1.34 (-1.08%) ▼|CAT704.05-36.16 (-4.89%) ▼|CL97.39+3.99 (+4.27%) ▲|CMCSA22.84+0.76 (+3.44%) ▲|COF203.43-3.23 (-1.56%) ▼|COP145.63-0.04 (-0.03%) ▼|COST1,018.21+19.90 (+1.99%) ▲|CRM250.29+8.51 (+3.52%) ▲|CSCO104.89-2.37 (-2.21%) ▼|CVS94.48+1.70 (+1.83%) ▲|CVX226.68-0.10 (-0.04%) ▼|DE643.62+7.08 (+1.11%) ▲|DHR229.75-4.11 (-1.76%) ▼|DIS113.13+1.30 (+1.16%) ▲|DUK125.40+4.73 (+3.92%) ▲|EMR160.29-2.82 (-1.73%) ▼|FDX303.92+5.69 (+1.91%) ▲|GD350.79+6.08 (+1.76%) ▲|GE293.54-2.34 (-0.79%) ▼|GEV827.42-98.50 (-10.64%) ▼|GILD157.19+3.62 (+2.36%) ▲|GM77.21+1.10 (+1.45%) ▲|GOOG320.76-10.19 (-3.08%) ▼|GOOGL324.22-10.54 (-3.15%) ▼|GS891.30-13.42 (-1.48%) ▼|HD327.73+13.59 (+4.33%) ▲|HON218.31+3.58 (+1.67%) ▲|IBM252.11+0.65 (+0.26%) ▲|INTC85.49-7.47 (-8.04%) ▼|INTU354.90+19.29 (+5.75%) ▲|ISRG443.85+15.73 (+3.67%) ▲|JNJ267.61+9.83 (+3.81%) ▲|JPM336.54+1.35 (+0.40%) ▲|KO95.34+2.66 (+2.87%) ▲|LIN510.36+9.79 (+1.96%) ▲|LLY1,306.69+35.94 (+2.83%) ▲|LMT589.91+38.40 (+6.96%) ▲|LOW204.37+7.81 (+3.97%) ▲|LRCX230.15-30.66 (-11.76%) ▼|MA633.21+10.59 (+1.70%) ▲|MCD252.63+6.38 (+2.59%) ▲|MDLZ65.19+2.45 (+3.91%) ▲|MDT96.59+3.56 (+3.83%) ▲|META648.85-48.67 (-6.98%) ▼|MMM175.56+0.82 (+0.47%) ▲|MO76.07+2.24 (+3.03%) ▲|MRK147.24-2.64 (-1.76%) ▼|MS183.97-3.04 (-1.63%) ▼|MSFT521.08-11.87 (-2.23%) ▼|MU856.49-57.18 (-6.26%) ▼|NEE81.90+3.62 (+4.62%) ▲|NFLX67.05+2.01 (+3.09%) ▲|NKE38.32+0.79 (+2.11%) ▲|NOW157.00+3.88 (+2.53%) ▲|NVDA212.21-9.76 (-4.40%) ▼|ORCL125.54-3.59 (-2.78%) ▼|PEP138.83+4.13 (+3.07%) ▲|PFE30.42+0.57 (+1.91%) ▲|PG165.59+8.75 (+5.58%) ▲|PLTR196.19-5.53 (-2.74%) ▼|PM201.74+4.28 (+2.17%) ▲|QCOM172.83-5.13 (-2.88%) ▼|RTX194.71+3.11 (+1.62%) ▲|SBUX101.91+2.83 (+2.86%) ▲|SCHW91.44-0.20 (-0.22%) ▼|SO93.82+3.43 (+3.79%) ▲|SPG212.04+6.49 (+3.16%) ▲|T22.74+0.83 (+3.79%) ▲|TMO676.54-17.48 (-2.52%) ▼|TMUS158.79+5.04 (+3.28%) ▲|TSLA374.58-11.89 (-3.08%) ▼|TXN279.50-5.15 (-1.81%) ▼|UBER69.07+1.45 (+2.14%) ▲|UNH424.98+7.98 (+1.91%) ▲|UNP298.09+10.22 (+3.55%) ▲|UPS101.52+1.95 (+1.96%) ▲|USB60.02+0.97 (+1.64%) ▲|V414.34+6.49 (+1.59%) ▲|VZ45.20+1.64 (+3.76%) ▲|WFC83.01+0.59 (+0.72%) ▲|WMT121.12+3.32 (+2.82%) ▲|XOM178.23+0.14 (+0.08%) ▲|
19 C
New York
Thursday, October 22, 2026

Tag: radiotherapy

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

64 research findings have been accepted, including three Proffered Paper presentations and three Rapid Oral presentations, spanning more than ten areas of oncology and...

Hengrui Pharma Previews ESMO Congress 2026 with 64 Research Findings Across Its Innovative Oncology Portfolio

64 findings accepted, including three Proffered Paper and three Rapid Oral presentations, spanning more than ten oncology and supportive care areas.More than ten studies...

Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development

– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology,...

Mercy Medical Center Expands Prostate Cancer Treatment Options With Advanced TrueBeam Technology

BALTIMORE, Oct. 13, 2026 /PRNewswire/ -- Mercy Medical Center is expanding advanced treatment options for men with prostate cancer through the enhanced capabilities of its...

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodiesTAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"...

Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options

FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care.RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ -- Accord...

Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform

MADISON, Wis., Sept. 27, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc.,...

Leo Cancer Care Unveils Bold Plans to Improve How Children Experience Radiotherapy, Following World-First Treatments

BOSTON, Sept. 27, 2026 /PRNewswire/ -- Leo Cancer Care has announced plans to further invest in the treatment experience for children undergoing radiation therapy....

Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 23, 2026 /CNW/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 23, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

PreludeDx™ Achieves New Milestones for DCIS Patients and DCISionRT® Testing

LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone...

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter,...

Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®

AHMEDABAD, India, Aug. 7, 2025 /PRNewswire/ -- Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRadiotherapy